25.43
price up icon1.56%   0.39
after-market アフターアワーズ: 25.08 -0.35 -1.38%
loading
前日終値:
$25.04
開ける:
$25.15
24時間の取引高:
756.48K
Relative Volume:
1.17
時価総額:
$1.80B
収益:
$80.89M
当期純損益:
$-144.73M
株価収益率:
-8.5623
EPS:
-2.97
ネットキャッシュフロー:
$-83.87M
1週間 パフォーマンス:
+0.91%
1か月 パフォーマンス:
+14.55%
6か月 パフォーマンス:
+98.98%
1年 パフォーマンス:
+293.65%
1日の値動き範囲:
Value
$23.89
$25.46
1週間の範囲:
Value
$23.51
$25.46
52週間の値動き範囲:
Value
$4.96
$27.60

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name
名前
Nurix Therapeutics Inc
Name
セクター
Healthcare (1182)
Name
電話
(415) 660-5320
Name
住所
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
職員
284
Name
Twitter
Name
次回の収益日
2024-10-14
Name
最新のSEC提出書
Name
NRIX's Discussions on Twitter

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-31 開始されました Truist Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-09 開始されました Barclays Overweight
2023-02-28 開始されました Oppenheimer Outperform
2022-10-11 開始されました Morgan Stanley Equal-Weight
2022-05-31 アップグレード Wells Fargo Equal Weight → Overweight
2022-02-10 開始されました Wells Fargo Equal Weight
2021-12-29 開始されました H.C. Wainwright Buy
2021-10-14 開始されました SVB Leerink Outperform
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-30 再開されました Piper Sandler Overweight
2021-04-30 開始されました RBC Capital Mkts Outperform
2021-04-14 開始されました Berenberg Buy
2020-11-19 開始されました Robert W. Baird Outperform
2020-08-18 開始されました JP Morgan Overweight
2020-08-18 開始されました Needham Buy
2020-08-18 開始されました Piper Sandler Overweight
2020-08-18 開始されました Stifel Buy
すべてを表示

Nurix Therapeutics Inc (NRIX) 最新ニュース

pulisher
09:17 AM

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

09:17 AM
pulisher
Nov 04, 2024

Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com

Nov 04, 2024
pulisher
Nov 03, 2024

(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India

Nov 02, 2024
pulisher
Nov 02, 2024

Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St

Oct 31, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia

Oct 30, 2024
pulisher
Oct 30, 2024

Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada

Oct 26, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

UBS sees upside for Nurix stock driven by promising NX-5948 data in CLL/SLL - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

UBS Group Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

What is HC Wainwright’s Forecast for NRIX FY2024 Earnings? - Defense World

Oct 24, 2024
pulisher
Oct 23, 2024

(NRIX) On The My Stocks Page - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 23, 2024

HC Wainwright Has Bullish Estimate for NRIX FY2024 Earnings - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World

Oct 23, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial - Clinical Trials Arena

Oct 21, 2024
pulisher
Oct 20, 2024

WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 20, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the - GlobeNewswire

Oct 19, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia - Yahoo Finance

Oct 19, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - The Manila Times

Oct 19, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics stock soars to 52-week high of $26.31 By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 52-Week HighHere's What Happened - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics stock soars to 52-week high of $26.31 - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

The Manufacturers Life Insurance Company Purchases 4,583 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics adds pharma veteran Anil Kapur to board - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics adds pharma veteran Anil Kapur to board By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Take off with Nurix Therapeutics Inc (NRIX): Get ready for trading - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - Defense World

Oct 16, 2024

Nurix Therapeutics Inc (NRIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nurix Therapeutics Inc (NRIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ring Christine
Chief Legal Officer
Nov 04 '24
Sale
25.00
3,290
82,250
28,084
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):